| pubmed-article:14657600 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14657600 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:14657600 | lifeskim:mentions | umls-concept:C0334590 | lld:lifeskim |
| pubmed-article:14657600 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:14657600 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:14657600 | lifeskim:mentions | umls-concept:C1514474 | lld:lifeskim |
| pubmed-article:14657600 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:14657600 | pubmed:dateCreated | 2003-12-5 | lld:pubmed |
| pubmed-article:14657600 | pubmed:abstractText | Anaplastic oligodendrogliomas (AO) are uncommon primary brain tumors whose natural history, prognosis, and optimal management are not yet fully understood. However, they are associated with a better prognosis and response to multimodality therapy based on specific molecular changes. In this multicenter retrospective study, we analyzed the clinical characteristics of patients with AO to identify prognostic factors that influence time to progression (TTP) and survival. | lld:pubmed |
| pubmed-article:14657600 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14657600 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14657600 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14657600 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14657600 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14657600 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14657600 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14657600 | pubmed:issn | 0030-2414 | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:HessKenneth... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:YungW K... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:BrunerJanet... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:BuysSaundra... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:PradosMichael... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:PuduvalliVina... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:JaeckleKurt... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:LevinVictor... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:McAllisterLes... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:DavisRichardR | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:TownsendJeann... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:SawayaRaymond... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:KyritsisAthan... | lld:pubmed |
| pubmed-article:14657600 | pubmed:author | pubmed-author:HashmiMasoodM | lld:pubmed |
| pubmed-article:14657600 | pubmed:copyrightInfo | Copyright 2003 S. Karger AG, Basel | lld:pubmed |
| pubmed-article:14657600 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14657600 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:14657600 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14657600 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14657600 | pubmed:pagination | 259-66 | lld:pubmed |
| pubmed-article:14657600 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:meshHeading | pubmed-meshheading:14657600... | lld:pubmed |
| pubmed-article:14657600 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14657600 | pubmed:articleTitle | Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. | lld:pubmed |
| pubmed-article:14657600 | pubmed:affiliation | University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. vpuduval@mdanderson.org | lld:pubmed |
| pubmed-article:14657600 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14657600 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:14657600 | pubmed:publicationType | Multicenter Study | lld:pubmed |
